ArticlePloS one2010
Human leukocyte antigens and HIV type 1 viral load in early and chronic infection: predominance of evolving relationships.
Article in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- Role of transmitted Gag CTL polymorphisms in defining replicative capacity and early HIV-1 pathogenesis.PLoS pathogens · 2012Trial
- Enterocyte Autoantibodies (GECAs) and HLA: Their Relationship with HIV Infection Pathogenesis.International journal of molecular sciences · 2026Review
- HLA-A*23 Is Associated With Lower Odds of Acute Retroviral Syndrome in Human Immunodeficiency Virus Type 1 Infection: A Multicenter Sub-Saharan African Study.Open forum infectious diseases · 2024Article
- Immunological Control of HIV-1 Disease Progression by Rare Protective HLA Allele.Journal of virology · 2022Article
- HLA-B*13, B*35 and B*39 Alleles Are Closely Associated With the Lack of Response to ART in HIV Infection: A Cohort Study in a Population of Northern Brazil.Frontiers in immunology · 2022Article
- Genome-wide association study reveals genetic variants associated with HIV-1C infection in a Botswana study population.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Immunosuppression in Medulloblastoma: Insights into Cancer Immunity and Immunotherapy.Current treatment options in oncology · 2021Review
- Immunogenetic determinants of heterosexual HIV-1 transmission: key findings and lessons from two distinct African cohorts.Genes and immunity · 2021Review
- Exome Sequencing Reveals a Putative Role for HLA-C*03:02 in Control of HIV-1 in African Pediatric Populations.Frontiers in genetics · 2021Article
- HIV-Specific, Ex Vivo Expanded T Cell Therapy: Feasibility, Safety, and Efficacy in ART-Suppressed HIV-Infected Individuals.Molecular therapy : the journal of the American Society of Gene Therapy · 2018Article
- Novel HLA class I associations with HIV-1 control in a unique genetically admixed population.Scientific reports · 2018Article
- HLA Class I Downregulation by HIV-1 Variants from Subtype C Transmission Pairs.Journal of virology · 2018Article
- Immunogenetic factors in early immune control of human immunodeficiency virus type 1 (HIV-1) infection: Evaluation of HLA class I amino acid variants in two African populations.Human immunology · 2018Article
- Conserved HIV Epitopes for an Effective HIV Vaccine.Journal of clinical & cellular immunology · 2017Article
- Replication Capacity of Viruses from Acute Infection Drives HIV-1 Disease Progression.Journal of virology · 2017Article
- Human Leukocyte Antigen (HLA) and Immune Regulation: How Do Classical and Non-Classical HLA Alleles Modulate Immune Response to Human Immunodeficiency Virus and Hepatitis C Virus Infections?Frontiers in immunology · 2017Review
- Article
- HLA Class-II Associated HIV Polymorphisms Predict Escape from CD4+ T Cell Responses.PLoS pathogens · 2015Article
- CD4:CD8 lymphocyte ratio as a quantitative measure of immunologic health in HIV-1 infection: findings from an African cohort with prospective data.Frontiers in microbiology · 2015Article
- Transmitted virus fitness and host T cell responses collectively define divergent infection outcomes in two HIV-1 recipients.PLoS pathogens · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundDuring untreated, chronic HIV-1 infection, plasma viral load (VL) is a relatively stable quantitative trait that has clinical and epidemiological implications. Immunogenetic research has established various human genetic factors, especially human leukocyte antigen (HLA) variants, as independent determinants of VL set-point. METHODOLOGY/PRINCIPAL
findingsTo identify and clarify HLA alleles that are associated with either transient or durable immune control of HIV-1 infection, we evaluated the relationships of HLA class I and class II alleles with VL among 563 seroprevalent Zambians (SPs) who were seropositive at enrollment and 221 seroconverters (SCs) who became seropositive during quarterly follow-up visits. After statistical adjustments for non-genetic factors (sex and age), two unfavorable alleles (A*3601 and DRB1*0102) were independently associated with high VL in SPs (p<0.01) but not in SCs. In contrast, favorable HLA variants, mainly A*74, B*13, B*57 (or Cw*18), and one HLA-A and HLA-C combination (A*30+Cw*03), dominated in SCs; their independent associations with low VL were reflected in regression beta estimates that ranged from -0.47+/-0.23 to -0.92+/-0.32 log(10) in SCs (p<0.05). Except for Cw*18, all favorable variants had diminishing or vanishing association with VL in SPs (p<or=0.86). CONCLUSIONS/SIGNIFICANCE: Overall, each of the three HLA class I genes had at least one allele that might contribute to effective immune control, especially during the early course of HIV-1 infection. These observations can provide a useful framework for ongoing analyses of viral mutations induced by protective immune responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.